Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • HOME
  • ABOUT US
  • POLICY HUB
  • OUR VALUES
  • OUR SERVICES
  • PRIVACY POLICY
  • CONTACT US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Deals PIC

Liaocheng University and Shanghai Maiboxing Biotechnology Sign RMB 19 Million Pact to Co‑Develop LCUGZ1007 – Next‑Generation E‑PDC Probody Drug Conjugate

Fineline Cube Sep 8, 2026
Company Deals PIC

China Biotech’s Panboron BNCT Hospital Signs Strategic Pact with OncoCare Cancer Centre HK – Launching Cross‑Border BNCT Oncology Cooperation

Fineline Cube Sep 8, 2026
Company Deals PIC

Guangdong Taienkang Completes Capital Increase in Procapzoom – Secures Exclusive China Rights to World‑First Ocular Surface Cell Therapy SZ018

Fineline Cube Sep 8, 2026
Company Deals PIC

HepaBio Therapeutics Raises Series A Strategic Funding From TriApex to Advance Organoid Technology and Next‑Generation Drug R&D Systems

Fineline Cube Sep 7, 2026
Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company

BD Opens Tianjin Life Health Innovation Center With Seven Clinical Training Centers – Establishing a Northern China Hub Built on an “Experience – Training – R&D” Trinity for High‑End Medical Devices

Fineline Cube Sep 9, 2026
Company Drug

CSPC Pharmaceutical Wins NMPA Clinical Trial Approval for SYH2083 Eye Drops – A Class 1 Innovative Small‑Molecule Ophthalmic Drug Targeting Ocular Surface Inflammation via T‑Cell Adhesion and Activation

Fineline Cube Sep 9, 2026
Company Drug

Henlius Organon Secure EU Marketing Approval for BILDYOS and BILPREVDA Denosumab Biosimilars

Fineline Cube Sep 22, 2025

Shanghai Henlius Biotech, Inc. (HKG: 2696) and Organon (NYSE: OGN) announced that the European Commission...

Company Drug

Innovent Secures 2nd NMPA Approval for Mazdutide – First Dual GLP‑1/GCGR Therapy for Type 2 Diabetes

Fineline Cube Sep 22, 2025

Innovent Biologics Ltd. (HKG: 1801) announced that its mazdutide injection (IBI362) has received its second...

Company Deals

AusperBio Secures $63 Million Series B2 Financing to Propel AHB‑137 Development

Fineline Cube Sep 22, 2025

AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. (collectively “AusperBio”) announced that it has closed...

Company Deals

Pfizer and Arvinas Pass Commercial Rights of Vepdegestrant to Third Party

Fineline Cube Sep 22, 2025

Pfizer Inc. (NYSE: PFE) and Arvinas, Inc. (NASDAQ: ARVN) announced that they are stepping back...

Company Drug

Guangdong Taienkang Secures NMPA Approval for Safinamide Generic

Fineline Cube Sep 19, 2025

Guangdong Taienkang Pharmaceutical Co., Ltd. (SHE: 301263) announced that the National Medical Products Administration (NMPA)...

Company Drug

Hengrui Pharma Secures Breakthrough Therapy Designation for SHR‑1501 in China

Fineline Cube Sep 19, 2025

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (HKG: 1276, SHA: 600276) announced that its investigational injectable SHR‑1501...

Others

GE Healthcare Eyes Sale of China Unit Amid Revenue Decline

Fineline Cube Sep 19, 2025

GE Healthcare Technologies Inc. (NASDAQ: GEHC) is reportedly exploring the sale of a stake in...

Company Drug

Hengrui Pharma Secures NMPA Approval for Two Novel Immune‑Inflammatory Drugs

Fineline Cube Sep 19, 2025

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that China’s National Medical Products...

Company Deals Drug Medical Device

GenSci Secures Exclusive Rights to ALK’s House Dust Mite Allergy Therapies in China

Fineline Cube Sep 18, 2025

Changchun GeneScience Pharmaceutical Co., Ltd. (GenSci) announced a strategic partnership with ALK (ALKB:DC / OMX:...

Company Drug

Jiangsu Hengrui Secures Priority Review for Trastuzumab Rezetecan in HER2‑Positive Breast Cancer

Fineline Cube Sep 18, 2025

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that the National Medical Products...

Company Drug

Chongqing Genrix Secures NMPA Trial Approval for GR2301 IL‑15 Antibody in Vitiligo

Fineline Cube Sep 18, 2025

Chongqing Genrix Biopharmaceutical Co., Ltd. (SHA: 688443) announced that the National Medical Products Administration (NMPA)...

Company Drug

Suzhou Zelgen Secures NMPA Approval for ZGGS34 TriTEs Targeting MUC17‑Positive Solid Tumors

Fineline Cube Sep 18, 2025

Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA: 688266) announced that the National Medical Products Administration (NMPA)...

Company Drug

Eli Lilly’s Orforglipron Outperforms Oral Semaglutide in ACHIEVE‑3 Phase 3 Trial

Fineline Cube Sep 18, 2025

Eli Lilly and Company (NYSE: LLY) announced positive topline results from the open‑label, randomized Phase 3...

Company Deals

Eisai China Partners with DSM‑Firmenich’s i‑Health to Bring Lactéol to Mainland China

Fineline Cube Sep 18, 2025

Eisai (TYO: 4523) China, operating through its subsidiary Eisai (Liaoning) Pharmaceutical Co., Ltd., announced a...

Company Deals

Biocytogen Eyes A‑Share Listing on Shanghai’s STAR Market to Fund Preclinical R&D Growth

Fineline Cube Sep 18, 2025

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315) has filed a prospectus announcing plans to seek...

Company Drug

Jiangsu Hengrui HRS‑5635 Seeks Breakthrough Therapy Designation for Chronic Hepatitis B

Fineline Cube Sep 18, 2025

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that its next‑generation small‑interfering RNA...

Company Deals

Roche Announces $2.4 B Acquisition of 89bio, Targeting Liver and Cardiometabolic Therapies

Fineline Cube Sep 18, 2025

Roche (SWX: ROG, OTCMKTS: RHHBY) announced today that it will acquire 89bio, Inc. (NASDAQ: ETNB)...

Company Drug

Eli Lilly’s Mounjaro Shows Promising Results in Children with Type 2 Diabetes

Fineline Cube Sep 18, 2025

A recent clinical study published by Eli Lilly & Co. (NYSE: LLY) demonstrates that the GLP‑1...

Company Deals

Siemens Healthineers and Stryker Forge Neurovascular Robotics Alliance

Fineline Cube Sep 18, 2025

Siemens Healthineers (ETR: SHL) and Stryker (NYSE: SYK) today announced a strategic partnership to co‑develop...

Drug Policy / Regulatory

China CDE Seeks Public Feedback on 98th Batch of Reference Standards for Generic Drugs

Fineline Cube Sep 18, 2025

The China Center for Drug Evaluation (CDE) has published a draft list of the 98th...

Posts pagination

1 … 153 154 155 … 718

Recent updates

  • BD Opens Tianjin Life Health Innovation Center With Seven Clinical Training Centers – Establishing a Northern China Hub Built on an “Experience – Training – R&D” Trinity for High‑End Medical Devices
  • CSPC Pharmaceutical Wins NMPA Clinical Trial Approval for SYH2083 Eye Drops – A Class 1 Innovative Small‑Molecule Ophthalmic Drug Targeting Ocular Surface Inflammation via T‑Cell Adhesion and Activation
  • Gilead Sciences Opens 182,000‑Square‑Foot Research Center at Foster City Headquarters – Expanding Oncology, Inflammation, and Research Data Science Capabilities as Part of a Three‑Project US Investment Program Through 2030
  • Windward Bio Reports Positive POLARIS‑1 Phase 2 Interim Results for HBM9378/WIN378 – An Ultra‑Long‑Acting TSLP Antibody in Asthma – as the Phase 3 Portion Begins
  • China’s NHC Issues Eye Health Services Work Plan for 2026–2030 – Setting 2030 Targets on Cataract Surgery Rates, Ophthalmologist Workforce Density, and County‑Level Vision Care Capacity
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company

BD Opens Tianjin Life Health Innovation Center With Seven Clinical Training Centers – Establishing a Northern China Hub Built on an “Experience – Training – R&D” Trinity for High‑End Medical Devices

Company Drug

CSPC Pharmaceutical Wins NMPA Clinical Trial Approval for SYH2083 Eye Drops – A Class 1 Innovative Small‑Molecule Ophthalmic Drug Targeting Ocular Surface Inflammation via T‑Cell Adhesion and Activation

Company

Gilead Sciences Opens 182,000‑Square‑Foot Research Center at Foster City Headquarters – Expanding Oncology, Inflammation, and Research Data Science Capabilities as Part of a Three‑Project US Investment Program Through 2030

Company Drug

Windward Bio Reports Positive POLARIS‑1 Phase 2 Interim Results for HBM9378/WIN378 – An Ultra‑Long‑Acting TSLP Antibody in Asthma – as the Phase 3 Portion Begins

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.